Hirosaki University   医学研究科

2018.04 ～ 2022.03

Hirosaki University   医学部   医学科

2010.10 ～ 2015.03

Hirosaki University   University Hospital   Respiratory medicine and Infectious Diseases   Assistant Professor  

2022.06 ～ Now

Hirosaki University   University Hospital   Respiratory medicine and Infectious Diseases   医員  

2017.10 ～ 201803

Hirosaki University   University Hospital   Respiratory medicine and Infectious Diseases   医員  

2017.04 ～ 201706

Hirosaki University   University Hospital   初期研修医  

2016.04 ～ 201703

八戸市立市民病院   呼吸器科・内科   医師

2021.04 ～ 2022.05

がん研究会有明病院   呼吸器科内科   医師

2019.04 ～ 2021.03

八戸市立市民病院   呼吸器科・内科   医師

2018.10 ～ 2019.03

青森県立中央病院   呼吸器内科   医師

2018.04 ～ 2018.09

青森労災病院   初期研修医

2015.04 ～ 2016.03

econd-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer.

Ogusu S, Harutani Y, Tozuka T, Saito R, Koyama J, Sakamoto H, Sonoda T, Tsuchiya-Kawano Y, Oba T, Kudo K, Gyotoku H, Nakatomi K, Ariyasu R.

Cancer Immunol Immunother   2023.11

Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients.

Tozuka T, Yanagitani N, Yoshida H, Manabe R, Ogusu S, Tsugitomi R, Sakamoto H, Amino Y, Ariyasu R, Uchibori K, Kitazono S, Seike M, Gemma A, Nishio M.

Invest New Drugs.   2023.6

Granulomatosis with Polyangiitis following COVID-19 in an Adolescent.

Nakamura Y, Okumura F, Nihei M, Chubachi K, Sakamoto H, Ishioka Y, Makiguchi T, Tanaka H, Taima K, Yajima N, Kurose A, Tasaka S.

Intern Med.   62 ( 4 )   589 - 593   2023.2

Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02).

Tanaka H, Sakamoto H, Akita T, Ohyanagi F, Kawashima Y, Tambo Y, Tanimoto A, Horiike A, Miyauchi E, Tsuchiya-Kawano Y, Yanagitani N, Nishio M.

Thorac Cancer.   2022.5